There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (SGEN) and Sanofi (SNYNF) with bullish sentiments.
Seattle Genetics (SGEN)
Needham analyst Chad Messer reiterated a Buy rating on Seattle Genetics today and set a price target of $254.00. The company’s shares closed last Thursday at $192.34.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.1% and a 44.4% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $195.85, representing a 0.5% upside. In a report issued on October 22, Oppenheimer also assigned a Buy rating to the stock with a $213.00 price target.
See today’s analyst top recommended stocks >>
Sanofi (SNYNF)
In a report released today, Trung Huynh from Credit Suisse maintained a Buy rating on Sanofi, with a price target of EUR105.00. The company’s shares closed last Thursday at $91.51.
According to TipRanks.com, Huynh is ranked #1692 out of 6994 analysts.
Currently, the analyst consensus on Sanofi is a Strong Buy with an average price target of $121.90, a 33.2% upside from current levels. In a report issued on October 23, Kepler Capital also maintained a Buy rating on the stock with a EUR99.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNYNF:
